Q-omics provides the consensus-scored RAB5IF profile across patient tissues and cancer cell-line models. RAB5IF expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAB5IF is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, RAB5IF RNA expression shows 19,109 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where RAB5IF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB5IF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB5IF survival associations across molecular data types. RAB5IF RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB5IF RNA expression–survival associations across cancer types. High RAB5IF expression shows unfavorable associations in UVM, ACC, LIHC, KIRC, KICH and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAB5IF RNA expression.
This table summarizes RAB5IF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB5IF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB5IF shows higher tumor expression in COAD, KIRP, LUAD, STAD, LIHC and BLCA. The COAD box plot shows higher RAB5IF RNA expression in tumor versus normal tissue (log2 FC = +1.011, t-test p < 0.001).
This table shows molecular features associated with RAB5IF in patient tissues and cancer cell lines. In patient samples, RAB5IF shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB5IF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
